Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI)-Reference-Cited by-同舟云学术

Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI)

Published:2021-02 Issue:1 Volume:60 Page:103011
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Cid Joan^ORCID,Pérez-Valencia Amanda Isabel,Torrente Miguel Ángel,Ávarez-Larrán Alberto,Díaz-Ricart Maribel,Esteve Jordi,Lozano Miquel

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine;Coppo;Res Pract Thromb Haemost,2019

2. ADAMTS13 and von Willebrand factor interactions;Zander;Curr Opin Hematol,2015

3. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease;Moschcowitz;Proc NY Pathol Soc,1924

4. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group;Rock;N Engl J Med,1991

5. Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic Purpura: a systematic review and meta-analysis;Owattanapanich;Clin Appl Thromb Hemost,2019

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exchange transfusion combined with artesunate (ET-AS) as a safe and effective therapy in severe P. falciparum malaria: a case series;BMC Infectious Diseases;2024-06-19

2. Uncommon Manifestation: Thrombotic Thrombocytopenic Purpura Presenting Solely as Petechial Rash;Cureus;2024-04-10

3. Generation and pathogenicity of autoantibodies associated to thrombosis and hemostasis;Exploration of Immunology;2024-02-05

4. Five years of caplacizumab – lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura;Journal of Thrombosis and Haemostasis;2023-10

5. Immune thrombotic thrombocytopenic purpura: pathogenesis and novel therapies: a narrative review;Annals of Blood;2023-09